F. Schlürmann

发表

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

A. Armstrong, N. Clarke, M. Oya, 2022, NEJM evidence.

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients

F. Joly, J. Malhaire, E. Voog, 2020, International journal of cancer.

Management of non-metastatic castrate-resistant prostate cancer: A systematic review.

G. Pignot, P. Barthélémy, Y. Loriot, 2018, Cancer treatment reviews.

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.

K. Bensalah, J. Bernhard, H. Lang, 2022, European urology oncology.

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

S. Oudard, G. Gravis, N. Houédé, 2022, International journal of cancer.

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

A. Armstrong, N. Clarke, M. Oya, 2022, Journal of Clinical Oncology.

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

N. Clarke, M. Oya, A. Thiery-Vuillemin, 2023, Journal of Clinical Oncology.

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

M. Oya, N. Mehra, C. Poehlein, 2023, The Lancet. Oncology.